SINGAPORE, May 27, 2025 — Leo International Group has made a significant move, acquiring a major share in SPOABG AG, a company listed on the Frankfurt Stock Exchange (FSE). This acquisition links Asia and Europe. The company is now known as Leo International Precision Health AG (LIPH AG), trading under the updated ticker symbols “LEOW.F” and “LEOW.DU”.

This event marks the first time in a century that a company founded in Taiwan has achieved mainboard listing on the Frankfurt Stock Exchange in Germany. This is a key moment in Leo International’s global expansion, highlighting its dedication to using AI to improve healthcare across the world.

A Vision Rooted in Humanity, Realized Globally
Leo International Group, established in 1926, is a family-run business based in Taiwan. Now in its fourth generation, the company’s goal is to “Care for People, Advancing Humanity.” The Group is involved in biomedical innovation, wealth management, and luxury lifestyle services.

With this new listing, Leo International plans to use Germany as a base to expand its AI-driven healthcare strategy, called the “Precision Health Trinity.” It also aims to create a global platform for investment and innovation for its subsidiaries and partners.

Why Frankfurt, Why Now?

The Frankfurt Stock Exchange, part of the Deutsche Börse Group, has a market capitalization of EUR 1.97 trillion and is a major global financial hub. In 2024, Germany’s biotech and medtech industries received EUR 1.6 billion in investment, a 70% increase from the previous year.

As healthcare increasingly relies on digital solutions, the digital pathology market is expected to grow from USD 8.1 billion in 2024 to USD 19.5 billion by 2031.

This makes Frankfurt an ideal starting point for Leo International’s Precision Health Trinity, which includes:

* AI-driven drug discovery for a wide range of diseases, including rare conditions

* AI-enabled diagnostics for precise treatment

* Community-based medical services through smart clinics

“The acquisition of a company listed on the Frankfurt Stock Exchange’s mainboard is a critical step in our global expansion,” said Leo Wang, Chairman of Leo International Group. “We will focus on precision health as a core part of our growth, using international capital markets to foster innovation and create value for everyone involved.”

Singapore: Building a Legacy Through Family Office Strategy
In addition to the Frankfurt expansion, Leo International announced the establishment of a Single Family Office (SFO) in Singapore. This office will manage wealth across generations and support the Group’s long-term goals for social impact and wealth succession.

Singapore has become a leading family office hub in Asia, with over 2,000 SFOs. Its stable political environment, clear regulations, and favorable tax policies make it a popular choice for wealthy families.

“Singapore offers a strong legal and asset protection framework,” said Kevin Foo of Leo International Family Office Singapore. “We plan to connect capital networks across Singapore, Greater China, and ASEAN through our platform, while increasing our investments in health technology and philanthropy focused on creating impact.”

Strategic Growth Through M&A and Global Capital
LIPH AG will be used as an investment tool for Leo International to support its growth strategy. By acquiring and integrating AI-health companies in Europe and Asia, the Group aims to quickly expand its operations, create synergies, and increase shareholder value.

The Group intends to attract sovereign wealth funds and global investors, using fair valuation methods in capital markets. The goal is to develop a strong, international precision health platform that drives the next wave of biomedical innovation.

“We are considering dual listings, ADR issuance, and collaborations with the London Stock Exchange Group,” said Dr. Joshua Lo, CEO of LIPH AG, who has previously worked at Portwell Inc. and other tech companies. “Our aim is to broaden our regional presence while meeting global healthcare needs.”

A Family Legacy, Reimagined for the Future
Leo International’s journey, from a family business in Taiwan to a global leader in health-tech, shows a blend of tradition and innovation. The Group’s values, developed over four generations, are now combined with industry relevance, advanced technology, and a commitment to social responsibility.

“As we position ourselves at the intersection of AI, pharmaceuticals, and intelligent diagnostics, our family office and listed entity serve as twin engines,” said Chairman Wang. “They power our commitment to both industrial growth and global impact.”

With an 80% stake in the newly renamed Frankfurt-listed company, Wang and the original Group shareholders are transferring their shares to gain access to international capital markets, in compliance with German legal and accounting standards.

The Road Ahead
From Singapore to Frankfurt, Leo International is building more than just a business; it is creating connections between continents, industries, and generations. As AI transforms healthcare and wealth shifts across borders, Leo’s Precision Health Trinity is set to become a major force in the biomedical field.

With strategic focus, family values, and global ambition, Leo International is not just participating in the conversation, it is leading it.

RELATED ITEMS:, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 

CONTACT: Leo International Group – Brand Marketing & PR Department
Shahad, Chief Marketing Officer / service@leointernationalgroup.com
Mofey, Marketing Manager / +886 981 666 331 / mofey.liu@leointernationalgroup.com

“`